| 1. |
- Valentini, Vincenzo, et al.
(författare)
-
Multidisciplinary Rectal Cancer Management : 2nd European Rectal Cancer Consensus Conference (EURECA-CC2)
- 2009
-
Ingår i: Radiotherapy and Oncology. - : Elsevier BV. - 0167-8140 .- 1879-0887. ; 92:2, s. 148-163
-
Forskningsöversikt (refereegranskat)abstract
- BACKGROUND AND PURPOSE: During the first decade of the 21st century a number of important European randomized studies were published. In order to help shape clinical practice based on best scientific evidence from the literature, the International Conference on 'Multidisciplinary Rectal Cancer Treatment: Looking for an European Consensus' (EURECA-CC2) was organized in Italy under the endorsement of European Society of Medical Oncology (ESMO), European Society of Surgical Oncology (ESSO), and European Society of Therapeutic Radiation Oncology (ESTRO). METHODS: Consensus was achieved using the Delphi method. The document was available to all Committee members as a web-based document customized for the consensus process. Eight chapters were identified: epidemiology, diagnostics, pathology, surgery, radiotherapy and chemotherapy, treatment toxicity and quality of life, follow-up, and research questions. Each chapter was subdivided by a topic, and a series of statements were developed. Each member commented and voted, sentence by sentence thrice. Sentences upon which an agreement was not reached after voting round # 2 were openly debated during a Consensus Conference in Perugia (Italy) from 11 December to 13 December 2008. A hand-held televoting system collected the opinions of both the Committee members and the audience after each debate. The Executive Committee scored percentage consensus based on three categories: "large consensus", "moderate consensus", and "minimum consensus". RESULTS: The total number of the voted sentences was 207. Of the 207, 86% achieved large consensus, 13% achieved moderate consensus, and only 3 (1%) resulted in minimum consensus. No statement was disagreed by more than 50% of the members. All chapters were voted on by at least 75% of the members, and the majority was voted on by >85%. CONCLUSIONS: This Consensus Conference represents an expertise opinion process that may help shape future programs, investigational protocols, and guidelines for staging and treatment of rectal cancer throughout Europe.
|
|
| 2. |
- Wiechec, Emilia, et al.
(författare)
-
A fragile site within the HPC1 region at 1q25.3 affecting RGS16, RGSL1, and RGSL2 in human breast carcinomas
- 2008
-
Ingår i: Genes, Chromosomes and Cancer. - : John Wiley & Sons. - 1045-2257 .- 1098-2264. ; 47:9, s. 766-780
-
Tidskriftsartikel (refereegranskat)abstract
- Genomic alterations affecting chromosome arm 1q are considered to be an early event in breast carcinogenesis and are correlated with good prognosis for the patients. In the search for new breast cancer susceptibility genes, we focused on three genes from the Regulator of G protein Signaling family clustered on 1q25.3 within the HPC1 region. RGS16, RGSL2, and RGSL1 encode proteins interacting with G proteins and accelerating termination of the G protein signaling. To evaluate the implication of these genes in somatic breast cancer, we analyzed a 154-kb segment at 1q25.3 using allelic imbalance (AI) mapping. A panel of 222 patients diagnosed with primary breast cancer was analyzed using newly identified, intragenic short tandem repeats (STRs). A high rate of AI (>50%) was found across the region and led to the identification of internal chromosomal breakpoints. A detailed mapping of the breakpoints revealed intragenic microdeletions affecting the coding regions of RGSL2, RGSL1, and the regulatory region of RGS16. The promoter region of RGS16 was found to be methylated in 10% of the tumors. A decrease in the RGS16 expression was found in tumors with chromosomal breakpoints, AI, and aberrant methylation. We found a significant association between AI of RGSL2 and localized disease, which correlated with good prognosis for patients with breast cancer. In conclusion, we found the 1q25.3 region to be highly unstable in breast tumors comprising a cluster of chromosomal breakpoints, intragenic microdeletions, frequent allelic imbalance correlating with long metastasis-free survival, and RGS16 promoter methylation affecting the protein expression.
|
|
